Study · Randomized controlled trial · n = 9,340 · 2016

8 results

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB

The New England journal of medicine13 Jun 2016Cited by 5,535 (Europe PMC)

PMID27295427PMCIDPMC4985288DOI10.1056/nejmoa1603827PepBankPUB-27295427

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high cardiovascular risk, liraglutide gave significantly fewer primary composite cardiovascular events than placebo.
In plain wordsIn adults with type 2 diabetes and high heart risk, fewer people on liraglutide had a heart attack, stroke or heart death than on placebo.
Peptide
Liraglutide
Outcome
DecreaseFirst occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke
Study
n = 9,340
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
HR
0.87 ratio
primary composite outcome
Source sentences
Summary
The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P=0.01 for superiority).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo.
Report a problemFND-2729542701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high cardiovascular risk, fewer patients died from cardiovascular causes with liraglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and high heart risk, fewer people on liraglutide died from heart and blood vessel causes than on placebo.
Peptide
Liraglutide
Outcome
DecreaseDeath from cardiovascular causes
Study
n = 9,340
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
HR
0.78 ratio
cardiovascular death
Source sentences
Summary
Fewer patients died from cardiovascular causes in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93; P=0.007).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo.
Report a problemFND-2729542702
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high cardiovascular risk, the rate of death from any cause was lower with liraglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and high heart risk, deaths from any cause were less frequent on liraglutide than on placebo.
Peptide
Liraglutide
Outcome
DecreaseDeath from any cause
Study
n = 9,340
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
HR
0.85 ratio
death from any cause
Source sentences
Summary
The rate of death from any cause was lower in the liraglutide group (381 patients [8.2%]) than in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P=0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo.
Report a problemFND-2729542703
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high cardiovascular risk, the rate of nonfatal myocardial infarction was nonsignificantly lower with liraglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and high heart risk, non-fatal heart attacks were not clearly different on liraglutide compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeNonfatal myocardial infarction
Study
n = 9,340
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The rates of nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure were nonsignificantly lower in the liraglutide group than in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo.
Report a problemFND-2729542704
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high cardiovascular risk, the rate of nonfatal stroke was nonsignificantly lower with liraglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and high heart risk, non-fatal strokes were not clearly different on liraglutide compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeNonfatal stroke
Study
n = 9,340
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The rates of nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure were nonsignificantly lower in the liraglutide group than in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo.
Report a problemFND-2729542705
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high cardiovascular risk, hospitalization for heart failure was nonsignificantly lower with liraglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and high heart risk, hospital stays for heart failure were not clearly different on liraglutide compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeHospitalization for heart failure
Study
n = 9,340
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The rates of nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure were nonsignificantly lower in the liraglutide group than in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo.
Report a problemFND-2729542706
07HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and high cardiovascular risk, gastrointestinal events were the most common adverse events leading to discontinuation of liraglutide.
In plain wordsIn adults with type 2 diabetes and high heart risk, stomach and gut problems were the most common side effects that made people stop liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedAdverse events leading to discontinuation
Study
n = 9,340
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The most common adverse events leading to the discontinuation of liraglutide were gastrointestinal events.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo.
Report a problemFND-2729542707
08HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and high cardiovascular risk, the incidence of pancreatitis was nonsignificantly lower with liraglutide than with placebo.
In plain wordsIn adults with type 2 diabetes and high heart risk, pancreatitis was not clearly different on liraglutide compared with placebo.
Peptide
Liraglutide
Outcome
No significant changePancreatitis incidence
Study
n = 9,340
Comparator
Placebo
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The incidence of pancreatitis was nonsignificantly lower in the liraglutide group than in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo.
Report a problemFND-2729542708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials14

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

14 trials · 8 ongoing · 3 completed · 1 stopped early · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2/3NCT07284511

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

McGill University Health Centre/Research Institute of the McGill University Health Centren = 10519 May 2026 to est. Jan 2029

Type 1 Diabetes · Type 1 Diabetes Mellitus · T1D · T1DM · T1DM - Type 1 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 27 May 2026

RecruitingPhase 3NCT06894784

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centren = 36est. Apr 2025 to est. Jan 2027

Diabetes Type 1

Trial page ClinicalTrials.govUpdated 30 Mar 2025

RecruitingPhase 4NCT06606821

The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

Tina Vilsbølln = 1241 Oct 2024 to est. 1 Aug 2028

Coronary Artery Disease · Coronary Microvascular Dysfunction · Overweight or Obesity · Stable Angina Pectoris · Chronic Coronary Artery Disease · Atherosclerosis Cardiovascular Disease

Trial page ClinicalTrials.govUpdated 22 May 2025

Active, not recruitingPhase 2/3NCT06363747

The Medically Reproducing Bariatric Surgery (MRB) II Study

Durham VA Medical Centern = 5024 Jun 2024 to est. 3 Nov 2025

Type 2 Diabetes · Obesity

Trial page ClinicalTrials.govUpdated 7 Feb 2025

Active, not recruitingPhase 4NCT07590219

Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity

University of Sao Paulo General Hospitaln = 3030 Mar 2024 to est. Apr 2028

Severe Obesity · Cardiovascular Function · Liraglutide · Childhood Obesity · Echocardiography · Speckle Tracking

Trial page ClinicalTrials.govUpdated 15 May 2026

RecruitingPhase 2NCT05478707

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

AdventHealth Translational Research Instituten = 475 Oct 2023 to est. 30 Jul 2028

Diabetes Mellitus, Type 1 · Endothelial Dysfunction

Trial page ClinicalTrials.govUpdated 15 Oct 2026

CompletedPhase not statedNCT05136287

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

Jose Seijas Amigon = 1401 Feb 2022 to 1 Jan 2024

Weight Loss · Diabetes Mellitus, Type 2 · Quality of Life · Safety Issues

Trial page ClinicalTrials.govUpdated 28 Feb 2024

RecruitingPhase 4NCT04575844

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

University of Virginian = 801 Nov 2020 to est. 30 Apr 2027

Metabolic Syndrome

Trial page ClinicalTrials.govUpdated 6 May 2026

WithdrawnEarly phase 1NCT04133922

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

University of Virginian = 014 Oct 2019 to est. Oct 2024

Type 1 Diabetes · Insulin Sensitivity/Resistance

Trial page ClinicalTrials.govUpdated 22 Mar 2022

RecruitingPhase not statedNCT03878706

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

University of Athensn = 2403 Nov 2017 to est. 30 Jun 2027

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 13 Mar 2026

CompletedPhase not statedResults postedNCT07465926

Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3

Chung Shan Medical Universityn = 451,0361 Jan 2017 to 31 Jan 2026

Cardiovascular-kidney-metabolic Syndrome · Cardiovascular Disease Risk Factor · Kidney Disease · Type 2 Diabetes · Obesity & Overweight

Trial page ClinicalTrials.govUpdated 22 Jun 2026

Status unknownPhase 4NCT04122716

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet

Signe Torekovn = 215Sept 2016 to est. Nov 2021

Obesity

Trial page ClinicalTrials.govUpdated 2 Nov 2020

Status unknownNot applicableNCT02930265

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese PLA General Hospitaln = 400Sept 2016 to est. Mar 2018

Ischemic Cardiomyopathy

Trial page ClinicalTrials.govUpdated 12 Oct 2016

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.